Shareholders meeting

15th July, 2026 The Corporate Relationship Department National Stock Exchange of India Limited BSE Limited Exchange Plaza, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Dalal Street, Bandra East, Mumbai 400 001. Mumbai 400 051. Scrip Code: 539523 Scrip Symbol: ALKEM Sub: Intimation under Regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“SEBI LODR Regulations”), covering the following: Notice convening the meeting of the equity shareholders of Alkem Laboratories Limited pursuant to the order of the Hon’ble National Company Law Tribunal, Mumbai Bench (“NCLT”) dated June 10, 2026 (“Order”) Ref: In the matter of scheme of amalgamation between Alkem Laboratories Limited (“Company”) and Adroit Biomed Limited (“ABL”) under Sections 230 to 232 read with other relevant provisions of the Companies Act, 2013 (“Scheme” or “Scheme of Amalgamation”). Dear Sir/Madam, We wish to inform that pursuant to the Order of the NCLT, a meeting of the equity shareholders of the Company will be held on Monday, August 17, 2026 at 11:00 a.m (IST) through electronic mode (video conference (“VC”) or other audio visual means (“OAVM”)) (“the Meeting”) to consider and if thought fit, approve, with or without modification(s), the Scheme of Amalgamation. Copy of the notice of the aforesaid Meeting along with explanatory statement and other documents annexed thereto as required under Sections 230 and 232 and Section 102 and other applicable provisions of the Companies Act, 2013 read with Rule 6 of the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016, is enclosed. The details pertaining to remote e-voting, e-voting during the Meeting and attending the Meeting through VC/OAVM have been set out in the Notice. The notice is being sent through e-mail to those equity shareholders whose e-mail addresses are registered with the Company/ Depository Participants. The notice along with the explanatory statement (including the annexures) are also available on the website of the Company at www.alkemlabs.com. The above is for your information, records and dissemination please. Sincerely, For Alkem Laboratories Limited Manish Narang President – Legal, Company Secretary & Compliance Officer Encl: a/a ALKEM LABORATORIES LIMITED Corporate Identification Number (CIN): L00305MH1973PLC174201 Registered Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai, Maharashtra, India, 400013 Tel.: +91 22 3982 9999, Fax: +91 22 2495 2955 Email: investors@alkem.com Website: www.alkemlabs.com NOTICE CONVENING THE MEETING OF THE EQUITY SHAREHOLDERS OF ALKEM LABORATORIES LIMITED PURSUANT TO THE ORDER DATED JUNE 10, 2026, OF THE HON’BLE NATIONAL COMPANY LAW TRIBUNAL, MUMBAI BENCH. MEETING DETAILS: Day : Monday Date : August 17, 2026 Time : 11.00 a.m. Mode of Meeting : As per the directions of the Hon’ble NCLT, Mumbai Bench, the meeting shall be conducted through video conferencing/other audio-visual means. Venue : In accordance with the MCA circulars the deemed venue of the Meeting shall be registered office of the Company i.e Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai, Maharashtra, India, 400013 REMOTE E-VOTING: Cut-off date for determining eligibility for : August 10, 2026 e-voting Remote e-voting start date and time : August 12, 2026 at 9:00 AM IST Remote e-voting end date and time : August 16, 2026 at 5:00 PM IST INDEX Contents Page No. 1. Notice convening the meeting of the equity shareholders of Alkem Laboratories Limited (“Transferee Company” 3 or “ALL”) pursuant to the order dated June 10, 2026, of the Hon’ble National Company Law Tribunal, Mumbai bench (“NCLT” or “Tribunal”) (“Notice”). 2. Explanatory Statement under Section(s) 102, 230 to 232 of the Companies Act, 2013 (“Act”) read with Rule 6 of 12 the Company (Compromises, Arrangements and Amalgamations) Rules, 2016 and other applicable provisions of the Act, and as required under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI”) (“Explanatory Statement”). Annexures 3. Scheme of Arrangement between Adroit Biomed Limited (“Transferor Company” or “ABL”) and the Transferee 27 Company under Sections 230-232 and other applicable provisions of the Act (“Scheme”), enclosed as Annexure 1. 4. Audited consolidated and standalone financial statements for the financial year ended March 31, 2026, of ALL, 48 as per the format prescribed under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 enclosed as Annexure 2. 5. Audited financial statements for the financial year ended March 31, 2026, of ABL, enclosed as Annexure 3. 66 6. Shareholding patterns of ALL and ABL, enclosed as Annexure 4A and 4B respectively. 116 7. Report adopted by the respective Board of Directors of the Transferor Company and the Transferee Company 124 dated February 11, 2026, and February 13, 2026 pursuant to Section 232(2)(c) of the Act enclosed as Annexure 5A and 5B respectively. 8. Certificate from the statutory auditors of ALL to the effect that the accounting treatment proposed in the 132 Scheme is in conformity with the accounting standards prescribed under Section 133 of the Act, enclosed as Annexure 6A. Certificate from the statutory auditors of ABL to the effect that the accounting treatment proposed in the 135 Scheme is in conformity with the accounting standards prescribed under Section 133 of the Act, enclosed as Annexure 6B. 9. Details of ongoing adjudications and recovery proceedings, prosecution initiated, and all other enforcement 139 action taken, if any, against ALL, their respective promoters and directors, enclosed as Annexure 7. The Notice, Explanatory Statement and Annexures 1 to 7 constitute a single and complete set of documents and should be read in conjunction with each other, as they form an integral set of documents. BEFORE THE NATIONAL COMPANY LAW TRIBUNAL, BENCH AT MUMBAI COMPANY SCHEME APPLICATION NO. 44/MB/2026 In the matter of the Companies Act, 2013; In the matter of Sections 230 - 232 and other applicable provisions of the Companies Act, 2013 read with Companies (Compromises, Arrangements and Amalgamation) Rules, 2016; In the matter of scheme of amalgamation between Adroit Biomed Limited and Alkem Laboratories Limited. Adroit Biomed Limited (CIN: U22100MH2009PLC197761), a public unlisted company incorporated ) under the provisions of Companies Act, 1956, having its registered office at Unit No F-115, 1st Floor, ) First Applicant Company/ Kanakia Zillion, BKC Annexure, LBS/CST Road, Kurla (West), Mumbai City, Mumbai, Maharashtra, ) Transferor Company India, 400070. ) Alkem Laboratories Limited (CIN: L00305MH1973PLC174201), a public listed company, ) Second Applicant incorporated under the provisions of the Companies Act, 1956, having its registered office at ) Company/ Transferee Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai, Maharashtra, India, 400013. ) Company Form No. CAA 2 (Pursuant to Section 230(3) of the Companies Act, 2013 and Rules 6 and 7 of the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016) Company Scheme Application No. 44/MB/2026 Alkem Laboratories Limited…Second Applicant Company / Transferee Company BEFORE THE NATIONAL COMPANY LAW TRIBUNAL, MUMBAI BENCH COMPANY SCHEME APPLICATION NO. 44/MB/2026 In the matter of Sections 230 - 232 and other applicable provisions of the Companies Act, 2013 read with Companies (Compromises, Arrangements and Amalgamation) Rules, 2016; In the matter of scheme of amalgamation between Adroit Biomed Limited and Alkem Laboratories Limited NOTICE CONVENING THE MEETING OF THE EQUITY SHAREHOLDERS OF ALKEM LABORATORIES LIMITED CONVENED AS PER THE DIRECTIONS OF THE NATIONAL COMPANY LAW TRIBUNAL, MUMBAI BENCH DATED JUNE 10, 2026 The Equity Shareholders of Alkem Laboratories Limited 1. Notice is hereby given that by an order dated June 10, 2026 (the “Order”) in [Showing first 8,000 characters — download PDF for full document]